
THE GLOBAL BURDEN OF CANCER


WITH 10 MILLION LIVES LOST EVERY YEAR, CANCER IS STILL A MAJOR CAUSE OF DEATHS WORLDWIDE¹.

IN 2020, THE NUMBER OF NEW CASES WAS 19 MILLION AND IS ESTIMATED TO REACH 28 MILLION BY 2040¹.

2024

2020





SUCH AN INCREASE WILL RESULT IN A TREMENDOUS LOSS OF LIFE AND COSTS TO SOCIETY.

INDEED, YEARLY COSTS OF ONCOLOGY PRESCRIPTION DRUGS PUT A HUGE PRESSURE ON HEALTHCARE SYSTEMS.

WITH A PRICE REDUCTION VARYING FROM 9% то 79%

(COMPARED TO REFERENCE PRODUCTS), **BIOSIMILARS COULD HELP REDUCE THESE** SPENDINGS AND BENEFIT MORE PATIENTS^{2,3}.

FOR EXAMPLE, IN THE U.S., THE USE OF GENERIC DRUGS AND BIOSIMILARS SAVED **\$18 BILLION ON ONCOLOGY** MEDICINES IN 2020⁴.



References:

(1) Sung H, Ferlay J, Siegal RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209–49. (2) Bangia I. Center for biosimilars. Biosimilar Discounts Vary by Category. 2020. Available at : https://www.centerforbiosimilars.com/view/biosimilar-discounts-vary-by-category- (accessed may 2023) (3) Dutta B, Huys I, Vulto AG, Simoens S. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!. BioDrugs. 2020;34(2):159-170. (4) Biosimilars Council. Biosimilar Medicines Produce Billions in Savings in U.S., Dramatically Reduce Oncology Spending Growth: Report. 2021. Available at: https://biosimilarscouncil.org/news/biosimilar-medicines-produce-billions-in-savings-in-u-s-dramatically-reduce-oncology-spending-report/ (accessed may 2023)

